JP2006525351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525351A5 JP2006525351A5 JP2006514176A JP2006514176A JP2006525351A5 JP 2006525351 A5 JP2006525351 A5 JP 2006525351A5 JP 2006514176 A JP2006514176 A JP 2006514176A JP 2006514176 A JP2006514176 A JP 2006514176A JP 2006525351 A5 JP2006525351 A5 JP 2006525351A5
- Authority
- JP
- Japan
- Prior art keywords
- claudin
- antibody
- kit
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 18
- 102000004106 Claudin-3 Human genes 0.000 claims 15
- 108090000599 Claudin-3 Proteins 0.000 claims 15
- 102000018157 Claudin-9 Human genes 0.000 claims 15
- 108050007295 Claudin-9 Proteins 0.000 claims 15
- 102000004161 Claudin-4 Human genes 0.000 claims 14
- 108090000601 Claudin-4 Proteins 0.000 claims 14
- 102000002029 Claudin Human genes 0.000 claims 12
- 108050009302 Claudin Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 208000037819 metastatic cancer Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 239000013603 viral vector Substances 0.000 claims 6
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 238000010222 PCR analysis Methods 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46690503P | 2003-04-30 | 2003-04-30 | |
| PCT/US2004/013436 WO2004098647A2 (en) | 2003-04-30 | 2004-04-30 | Claudins’ underexpression as markers of tumor metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006525351A JP2006525351A (ja) | 2006-11-09 |
| JP2006525351A5 true JP2006525351A5 (enExample) | 2007-06-07 |
Family
ID=33434995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006514176A Pending JP2006525351A (ja) | 2003-04-30 | 2004-04-30 | ガンを診断および治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040253211A1 (enExample) |
| EP (1) | EP1620732A2 (enExample) |
| JP (1) | JP2006525351A (enExample) |
| CN (1) | CN100575955C (enExample) |
| CA (1) | CA2523870A1 (enExample) |
| MX (1) | MXPA05011644A (enExample) |
| NO (1) | NO20055449L (enExample) |
| WO (1) | WO2004098647A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| AU2007332473B2 (en) * | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| JPWO2008114733A1 (ja) | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| KR101741898B1 (ko) | 2015-05-27 | 2017-06-01 | 울산대학교 산학협력단 | Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5554388A (en) * | 1989-02-25 | 1996-09-10 | Danbiosyst Uk Limited | Systemic drug delivery compositions comprising a polycationi substance |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
| GB9419979D0 (en) * | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
| GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
| GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
| AU3583797A (en) * | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Enhancement of cancer cell death |
| AU751182B2 (en) * | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
| GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| US6248864B1 (en) * | 1997-12-31 | 2001-06-19 | Adherex Technologies, Inc. | Compounds and methods and modulating tissue permeability |
| US7279294B2 (en) * | 2000-04-03 | 2007-10-09 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Tumor markers in ovarian cancer |
| CN1234727C (zh) * | 2000-06-01 | 2006-01-04 | 北京双鹭药业股份有限公司 | 人胸腺素α原基因突变体合成、表达及应用 |
| AU2003217397A1 (en) * | 2002-02-14 | 2003-09-04 | The Johns Hopkins University School Of Medecine | Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer |
-
2004
- 2004-04-30 US US10/836,421 patent/US20040253211A1/en not_active Abandoned
- 2004-04-30 CN CN200480018784A patent/CN100575955C/zh not_active Expired - Fee Related
- 2004-04-30 JP JP2006514176A patent/JP2006525351A/ja active Pending
- 2004-04-30 EP EP04751031A patent/EP1620732A2/en not_active Withdrawn
- 2004-04-30 CA CA002523870A patent/CA2523870A1/en not_active Abandoned
- 2004-04-30 WO PCT/US2004/013436 patent/WO2004098647A2/en not_active Ceased
- 2004-04-30 MX MXPA05011644A patent/MXPA05011644A/es not_active Application Discontinuation
-
2005
- 2005-11-17 NO NO20055449A patent/NO20055449L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2491222T3 (es) | Marcadores de expresión génica para el pronóstico de cáncer colorrectal | |
| CN102667472B (zh) | Tivozanib应答预测 | |
| JP2012506253A (ja) | 大腸癌関連マーカーを用いた大腸癌の診断キット、及びそれを用いた大腸癌の診断方法 | |
| KR102341336B1 (ko) | 만성간질환의 예후 예측용 바이오마커 조성물 | |
| CN103097548A (zh) | 基于多癌症侵袭相关机制的生物标记 | |
| WO2010151789A1 (en) | Salivary transcriptomic and microbial biomarkers for pancreatic cancer | |
| JP2011517937A5 (enExample) | ||
| CN107208159A (zh) | 宿主dna作为克罗恩氏病的生物标记物 | |
| JP2006525351A5 (enExample) | ||
| KR20110042678A (ko) | 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단 | |
| CN108884495B (zh) | 基因标记预测肝细胞癌对经导管动脉化疗栓塞(tace)的应答 | |
| WO2011036256A1 (en) | Methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor | |
| KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
| US20130190321A1 (en) | Methods and compositions relating to proliferative disorders of the prostate | |
| ES2380651T3 (es) | Biomarcadores y procedimientos para determinar la sensibilidad a moduladores de recpetor 2 del factor de crecimiento endotelial vascular | |
| US10895574B2 (en) | Left-right gene expression signature for triple negative breast cancer | |
| KR102343240B1 (ko) | 대장암 환자에서 세툭시맙에 대한 내성 예측용 바이오마커 조성물 | |
| CN118613596A (zh) | 用于检测区分侵袭性前列腺癌与惰性形式的生物标志物以及侵袭性前列腺癌的治疗 | |
| CN113862357A (zh) | 基于生物标志物预测直肠癌对术前放化疗联合全直肠系膜切除术敏感性的产品及其用途 | |
| KR20220061425A (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| KR102788247B1 (ko) | 혈관 육종 진단용 조성물, 키트 및 혈관 육종 진단을 위한 정보제공방법 | |
| US20240093307A1 (en) | Serum exosomal sf3b4 marker composition for diagnosing early stage hepatocellular carcinoma for noninvasive in vitro diagnosis | |
| KR102259708B1 (ko) | 대장암에 대한 항암제 감수성 예측을 위한 신규 바이오마커 | |
| GB2630774A (en) | Lung cancer biomarkers | |
| CN119619512A (zh) | Fkbp9检测剂在制备肝癌诊断或预后评估的产品中的应用 |